Yahoo Movies
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting
The "How I Met Your Father" actress shared that it's an emotional struggle to leave her sick child at home while she's working.
DALLAS, August 11, 2022--NETSTREIT Corp. (NYSE: NTST) ("NTST" or the "Company"), announced today the closing of an inaugural $600 million sustainability-linked senior unsecured credit facility (the "Credit Facility"), consisting of a $400 million senior unsecured revolving credit facility (the "Revolver") and a new $200 million senior unsecured term loan (the "Term Loan"), with an additional $400 million accordion feature. The Revolver refinanced and upsized NTST’s existing $250 million senior u
SAN FRANCISCO, August 11, 2022--PagerDuty (NYSE: PD), a leader in digital operations management, today announced the appointment of Bill Losch to the company’s Board of Directors. Losch, whose most recent operational role was as Chief Financial Officer (CFO) of Okta, brings more than three decades of successful experience providing financial and operational leadership for high-performing SaaS companies.
DALLAS, August 11, 2022--NETSTREIT Corp. (NYSE: NTST) (the "Company") announced today that the underwriters of its previously announced public offering, which closed on August 8, 2022, have exercised in full their option to purchase 1,350,000 additional shares of common stock at the price to the public of $20.20 per share in connection with the forward sale agreements described below. The closing of the option exercise is expected to occur on August 12, 2022, subject to customary closing conditi
Stocks finished Thursday's trading session mixed as traders failed to build on Wednesday's rally that saw the Nasdaq gain nearly 3%.
COLMAR, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Dorman Products, Inc. (NASDAQ:DORM) is announcing today the release of 300 new auto parts, a third of which are aftermarket-exclusives. The new products join an expansive catalog of more than 118,000 aftermarket solutions that advance the company’s mission of giving repair professionals and owners greater freedom to fix a wide range of passenger and commercial vehicles. This month’s featured new products include four Dorman® OE FIX™ parts, adding to
TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $4.7 Million in Q2’22Approximately 30,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 5,700 Unique Eye Care Professionals; Launch to Date, Approximately 7,700 Unique Eye Care Professionals Have Written Prescriptions for TYRVAYAExpanded Patient Access to TYRVAYA, With Medicare Part D Access Expected by Q4’22, and As Early As September 2022Operating Expense Streamlining Plan to Maxim
Kits Eyecare Ltd. (KITS) (TSX: KITS) Canada's largest direct-to-consumer eyeglasses manufacturer and digital eyecare provider has released its financial results for the second quarter of 2022.
Announced new clinical trial collaboration with Menarini Group to evaluate ONA-XR plus elacestrant in metastatic breast cancer Results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary presented at the 2022 ASCO Annual Meeting Preliminary results from multiple clinical trials planned for Q4 2022 On track for development candidate selection of CLDN6xCD3 bispecific in Q4 2022 PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (
ALBANY, NY, Aug. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Soluna Holdings, Inc. (“SHI” or the “Company”), (NASDAQ: SLNH), the parent company of Soluna Computing, Inc. (“SCI”), a developer of green data centers for cryptocurrency mining and other intensive computing, today announced the initial funding of up to $12.5 million from funds managed by Spring Lane Capital, a private equity firm focused on hybrid project capital for sustainability solutions in the energy, food, water, waste and t
CES Energy Solutions Corp. ("CES" or the "Company") (TSX: CEU) (OTC: CESDF) announced today the Company's results for the three and six months ended June 30, 2022.
Received FDA clearance of IND application for Phase 2 trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients First patient dosed in Phase 1b trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients in Canada, the United Kingdom and Australia Reported positive topline results from Phase 2a trial of tegoprubart demonstrating safety, target engagement, and biomarker response in patients living with amyotrophic lateral scleros
WAYNE, Pa. and ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that on August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board. Mr. Boyd and Dr. Maher’s resignations from the Board, effec
— Embark Has Perfect Safety Record In NHTSA ADS Crash Data Release — — Embark Completes Successful Public Demonstration of Emergency Vehicle Interaction Capability — — Embark Revises 2022 Free Cash Flow Spend on Process Improvements and Efficiencies and Extends Operational Runway— SAN FRANCISCO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Embark Technology, Inc. (Nasdaq: EMBK) (“Embark”), a leading developer of autonomous technology for the trucking industry, today announced financial results for the quar
LOS ANGELES, August 11, 2022--System1, Inc. (NYSE: SST) ("System1" or the "Company"), an omnichannel customer acquisition marketing platform, announced its financial results for the second quarter of 2022.
Total Q2 2022 revenue of $7.4 million, up 139% from prior yearRecently launched ALKINDI SPRINKLE® and Carglumic Acid continue to show robust growthDivestiture of hospital products division to focus on rare disease strategyU.S. Food and Drug Administration (FDA) Approval of Zonisade™ (zonisamide oral suspension) DEER PARK, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for
Q2 Total Revenue Increased 9% Year-over-Year to $89.1 millionQ2 Gross Merchandise Value Increased 8% Year-over-Year to $483.5 millionQ2 Adjusted EBITDA was ($9.8) million with (11.0%) margins REDWOOD CITY, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Poshmark, Inc. (NASDAQ: POSH), a leading social marketplace for new and secondhand style, today announced financial results for the second quarter ended June 30, 2022. The Company posted net revenues of $89.1 million in the second quarter of 2022, whic
CAMBRIDGE, Mass., August 11, 2022--Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., August 11, 2022--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.
PALO ALTO, Calif., August 11, 2022--Hippo, (NYSE: HIPO), the home insurance group focused on proactive home protection, today announced its consolidated financial results for the three months that ended June 30, 2022.